Clovis testing cancer drug on U.S. patient
Boulder-based Clovis (Nasdaq: CLVS) is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.
“The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug,´ said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
The company plans on filing a new drug application by mid-2015, after several more months of testing.
Testing of CO-1686 first occurred in Japan in the first quarter.
Boulder-based Clovis (Nasdaq: CLVS) is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.
“The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug,´ said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.
The company…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
